MC Re Spiro OOD
- Address
- lock Available on a paid plan
Nervous System Diseases
The clinical program at MC Re Spiro OOD explores insomnia disorder in children and adolescents, seeking to determine the safest and most effective dose of a new sleep‑promoting medication and to improve nighttime sleep quality.
- Assess safety and efficacy of daridorexant in pediatric patients
- Measure total sleep time using polysomnography
- Identify optimal dosing range for ages 10‑17
- Evaluate impact on daytime functioning and cognition
- Support regulatory approval for pediatric insomnia treatment
The research team collaborates closely with local healthcare providers to advance treatment options for young patients struggling with sleep disturbances.
Respiratory Tract Diseases
Studies conducted at the Razgrad facility address chronic obstructive pulmonary disease, asthma and related respiratory conditions, testing innovative inhaled drugs and biologic agents to lower exacerbation rates and enhance lung function.
- Evaluate CHF6001 as an add‑on to triple therapy for COPD
- Compare benralizumab add‑on versus high‑dose inhaled therapy in eosinophilic asthma
- Demonstrate therapeutic equivalence of two CHF5993 inhaler formulations
- Assess reduction in moderate and severe exacerbations over a year
- Investigate treatment strategies for mild to moderate asthma and chronic bronchitis
MC Re Spiro OOD’s respiratory research aims to provide new therapeutic choices for patients across Bulgaria and the wider European region.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Chiesi Farmaceutici S.p.A.2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.5trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MC Re Spiro OOD
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 3 | Unknown | 2025-04-29 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.